Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERVE-102 in Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease
NCT06164730Phase 1Recruiting
- Sponsor
- Verve Therapeutics
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- CRISPR-Cas9, Small Interfering RNA (siRNA), Antisense DNA
- Countries
- 6
01
Overview
Phase 1, open-label trial of VERVE-102 in heterozygous familial hypercholesterolemia (HeFH) and coronary artery disease (CAD) (10 cohorts), sponsored by Verve Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Started Apr 2024; status: recruiting.
02
Drugs
VERVE-102
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06164730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164730.